114
Participants
Start Date
February 5, 2015
Primary Completion Date
July 27, 2016
Study Completion Date
January 24, 2017
Volanesorsen
300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks.
Placebo
Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
IONIS Investigative Site, Berlin
IONIS Investigative Site, Marseille
IONIS Investigative Site, Dijon
IONIS Investigative Site, Towson
IONIS Investigative Site, Norfolk
IONIS Investigative Site, Benson
IONIS Investigative Site, Morrisville
IONIS Investigative Site, Chapel Hill
IONIS Investigative Site, Wilson
IONIS Investigative Site, Raleigh
IONIS Investigative Site, Farmville
IONIS Investigative Site, Greenville
IONIS Investigative Site, Wilson
IONIS Investigative Site, Miami
IONIS Investigative Site, Boca Raton
IONIS Investigative Site, Marion
IONIS Investigative Site, Cincinnati
IONIS Investigative Site, Kettering
IONIS Investigative Site, Grandville
IONIS Investigative Site, Cologne
IONIS Investigative Site, Sterling
IONIS Investigative Site, Kansas City
IONIS Investigative Site, Salisbury
IONIS Investigative Site, Oklahoma City
IONIS Investigative Site, Paris
IONIS Investigative Site, Houston
IONIS Investigative Site, Salt Lake City
IONIS Investigative Site, Encinitas
IONIS Investigative Site, San Francisco
IONIS Investigative Site, Portland
IONIS Investigative Site, Seattle
IONIS Investigative Site, Boston
IONIS Investigative Site, North Massapequa
IONIS Investigative Site, Providence
IONIS Investigative Site, Vancouver
IONIS Investigative Site, London
IONIS Investigative Site, Chicoutimi
IONIS Investigative Site, Sainte-Foy
IONIS Investigative Site, Saint-Herblain
IONIS Investigative Site, Dresden
IONIS Investigative Site, Amsterdam
IONIS Investigative Site, Rotterdam
IONIS Investigative Site, Utrecht
IONIS Investigative Site, Manchester
IONIS Investigative Site, Peterborough
Lead Sponsor
Collaborators (1)
Akcea Therapeutics
INDUSTRY
Ionis Pharmaceuticals, Inc.
INDUSTRY